Edition:
United States

Intercept Pharmaceuticals Inc (ICPT.OQ)

ICPT.OQ on NASDAQ Stock Exchange Global Select Market

66.85USD
20 Oct 2017
Change (% chg)

$-0.01 (-0.01%)
Prev Close
$66.86
Open
$67.47
Day's High
$67.50
Day's Low
$64.80
Volume
654,122
Avg. Vol
349,355
52-wk High
$140.87
52-wk Low
$54.98

Chart for

About

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic... (more)

Overall

Beta: -2.04
Market Cap(Mil.): $1,677.93
Shares Outstanding(Mil.): 25.10
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 89.38 16.52
EPS (TTM): -- -- --
ROI: -- 2.39 11.32
ROE: -- 3.35 15.18

Intercept does not expect restrictive boxed warning for liver drug

Intercept Pharmaceuticals Inc said on Monday its liver drug, Ocaliva, could carry a boxed warning to help ensure proper dosing but the drugmaker also said it does not expect the updated labeling to be restrictive, sending its shares higher.

Sep 25 2017

UPDATE 2-Intercept does not expect restrictive boxed warning for liver drug

Sept 25 Intercept Pharmaceuticals Inc said on Monday its liver drug, Ocaliva, could carry a boxed warning to help ensure proper dosing but the drugmaker also said it does not expect the updated labeling to be restrictive, sending its shares higher.

Sep 25 2017

Intercept Pharma says possible Ocaliva boxed warning will not be restrictive

Sept 25 Intercept Pharmaceuticals Inc said on Monday an update to the label of its liver drug, Ocaliva, could include a boxed warning to help ensure proper dosing of patients, but added that it did not expect the change to be restrictive.

Sep 25 2017

BRIEF-Intercept Pharmaceuticals comments on Ocaliva safety and dosing in liver disease patients​

* Intercept Pharmaceuticals Inc comments on Ocaliva (obeticholic acid) safety and dosing in primary biliary cholangitis (PBC) patients​

Sep 25 2017

FDA warns of death, liver injury risks from Intercept's drug

The U.S. Food and Drug Administration (FDA) warned on Thursday that Intercept Pharmaceuticals Inc's drug Ocaliva was being incorrectly dosed in some patients with a rare liver disease, increasing the risk of liver injury and death.

Sep 21 2017

FDA warns of death, liver injury risks from Intercept's drug

The U.S. Food and Drug Administration (FDA) warned on Thursday that Intercept Pharmaceuticals Inc's drug Ocaliva was being incorrectly dosed in some patients with a rare liver disease, increasing the risk of liver injury and death.

Sep 21 2017

UPDATE 1-FDA warns of death, liver injury risks from Intercept's drug

Sept 21 The U.S. Food and Drug Administration (FDA) warned on Thursday that Intercept Pharmaceuticals Inc's drug Ocaliva was being incorrectly dosed in some patients with a rare liver disease, increasing the risk of liver injury and death.

Sep 21 2017

FDA warns of liver injury, death risks from Intercept's drug

Sept 21 The U.S. Food and Drug Administration (FDA) warned on Thursday that Intercept Pharmaceuticals Inc's drug Ocaliva was being incorrectly dosed in some patients with a rare liver disease, increasing the risk of liver injury and death.

Sep 21 2017

BRIEF-Intercept announces positive results from the phase 2 AESOP trial for treatment of patients with primary sclerosing cholangitis

* Intercept announces positive results from the phase 2 AESOP trial evaluating OCA for the treatment of patients with primary sclerosing cholangitis

Jul 31 2017

BRIEF-Intercept Pharmaceuticals reports qtrly loss per share $3.46

* Intercept Pharmaceuticals reports second quarter 2017 financial results and provides business update

Jul 31 2017

Earnings vs. Estimates